All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Natural Killer (NK) cells are regulated by interactions between Killer-Immunoglobulin-Like Receptors (KIRs) and their corresponding Human Leukocyte Antigen (HLA) ligands. KIRs can be grouped into either inhibitory (KIR A) or activating and inhibitory receptors (KIR B). KIR A negatively regulate NK cell-mediated killing of HLA class I-expressing tumors. Lack of KIR–HLA class I interactions has been associated with antitumor efficacy and increased survival in patients with AML in CR after haploidentical stem cell transplantation from KIR-mismatched donors. Lirilumab is an anti-KIR monoclonal antibody, which is designed to activate NK cells thereby aiding their activation by blocking their inhibitory receptors.
Norbert Vey from the Paoli-Calmettes Institute, Marseille, France, presented at the 59th American Society of Hematology (ASH) Annual meeting, Atlanta, GA, results from the phase II EFFIKIR randomized study (NCT01687387), which is assessing lirilumab monotherapy as maintenance therapy for elderly patients with AML in first Complete Remission (CR1). The main objectives of this study are to evaluate whether lirilumab could improve Leukemia Free Survival (LFS) and to assess two dose schedules including continuous (CONT) or intermittent (INT) full KIR occupancy.
Overall, 152 AML patients aged 60–80 years in CR1 following standard induction were randomized to receive placebo (n = 51, median age = 69 years) or lirilumab (0.1 mg/kg q for 12 weeks [INT, n = 50, median age = 70 years] or 1 mg/kg q for 4 weeks [CONT, n = 51, median age = 70 years]). The primary endpoint of the study was Leukemia Free Survival (LFS) by Independent Review Committee (IRC).
In an interview with the AML Global Portal (AGP), Norbert Vey, noted that single agent “lirilumab administered for up to 24 cycles was well tolerated”. However, the findings of the phase II EFFIKIR trial were “negative” as lirilumab did not result in a statistically significant “improvement of LFS in the challenging setting of maintenance in AML in elderly patients” in CR1.
Furthermore, there were no significant difference observed between the lirilumab arms and plaebo but reverse trends suggesting a clinical impact of intermittent (favorable trend) versus continuous (detrimental trend) KIR blockade.
References